This HTML5 document contains 99 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n25http://linked.opendata.cz/resource/mesh/concept/
n7http://linked.opendata.cz/resource/drugbank/company/
n29http://linked.opendata.cz/resource/drugbank/dosage/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00478/identifier/wikipedia/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00478/identifier/pharmgkb/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00478/identifier/kegg-compound/
n12http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB00478/identifier/bindingdb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00478/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n28http://www.rxlist.com/cgi/generic/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00478/identifier/pubchem-substance/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00478/identifier/kegg-drug/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00478/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n24http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n17http://www.drugs.com/cdi/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00478/identifier/national-drug-code-directory/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00478/identifier/chemspider/
n18http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00478
rdf:type
n3:Drug
n3:description
An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza. [PubChem]
n3:dosage
n29:271B5A7B-363D-11E5-9242-09173F13E4C5 n29:271B5A7C-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
25 to 30 hours in young adults (22 to 44 years old). Approximately 32 hours in elderly (71 to 79 years old) and in patients with chronic liver disease. Approximately 13 to 38 hours in children (4 to 8 years old).
n3:indication
For the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults.
n3:manufacturer
n7:271B5A6D-363D-11E5-9242-09173F13E4C5 n7:271B5A6E-363D-11E5-9242-09173F13E4C5 n7:271B5A6B-363D-11E5-9242-09173F13E4C5 n7:271B5A6C-363D-11E5-9242-09173F13E4C5 n7:271B5A6F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00478 n12:DB00478
dcterms:title
Rimantadine
adms:identifier
n9:PA164748038 n10:Rimantadine n14:5071 n15:46505973 n20:4893 n21:DB00478 n22:50216627 n23:0456-0521-01 n26:C07236 n27:D08483
n3:mechanismOfAction
The mechanism of action of rimantadine is not fully understood. Rimantadine appears to exert its inhibitory effect early in the viral replicative cycle, possibly inhibiting the uncoating of the virus. Genetic studies suggest that a virus protein specified by the virion M2 gene plays an important role in the susceptibility of influenza A virus to inhibition by rimantadine.
n3:packager
n7:271B5A5E-363D-11E5-9242-09173F13E4C5 n7:271B5A5C-363D-11E5-9242-09173F13E4C5 n7:271B5A5D-363D-11E5-9242-09173F13E4C5 n7:271B5A5A-363D-11E5-9242-09173F13E4C5 n7:271B5A5B-363D-11E5-9242-09173F13E4C5 n7:271B5A58-363D-11E5-9242-09173F13E4C5 n7:271B5A59-363D-11E5-9242-09173F13E4C5 n7:271B5A65-363D-11E5-9242-09173F13E4C5 n7:271B5A66-363D-11E5-9242-09173F13E4C5 n7:271B5A63-363D-11E5-9242-09173F13E4C5 n7:271B5A64-363D-11E5-9242-09173F13E4C5 n7:271B5A61-363D-11E5-9242-09173F13E4C5 n7:271B5A62-363D-11E5-9242-09173F13E4C5 n7:271B5A5F-363D-11E5-9242-09173F13E4C5 n7:271B5A60-363D-11E5-9242-09173F13E4C5 n7:271B5A69-363D-11E5-9242-09173F13E4C5 n7:271B5A6A-363D-11E5-9242-09173F13E4C5 n7:271B5A67-363D-11E5-9242-09173F13E4C5 n7:271B5A68-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Following oral administration, rimantadine is extensively metabolized in the liver with less than 25% of the dose excreted in the urine as unchanged drug.
n3:synonym
SID29215455 Rimantadin Rimantadine
n3:toxicity
Oral LD<sub>50</sub> in rats is 640 mg/kg. Overdoses of a related rug, amantadine, have been reported with adverse reactions consisting of agitation, hallucinations, cardiac arrhythmia and death.
n3:proteinBinding
Approximately 40% over typical plasma concentrations.
n3:salt
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Rimantadine.htm
n24:hasConcept
n25:M0019119
foaf:page
n17:rimantadine.html n28:rimantadine.htm
n3:IUPAC-Name
n4:271B5A81-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5A87-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5A86-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5A83-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5A84-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5A85-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5A7F-363D-11E5-9242-09173F13E4C5 n4:271B5A96-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5A7D-363D-11E5-9242-09173F13E4C5 n4:271B5A80-363D-11E5-9242-09173F13E4C5 n4:271B5A98-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5A7E-363D-11E5-9242-09173F13E4C5
n18:hasATCCode
n19:J05AC02
n3:H-Bond-Acceptor-Count
n4:271B5A8D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5A8E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5A88-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5A89-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5A8B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5A8A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5A8C-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed, with the tablet and syrup formulations being equally absorbed after oral administration.
n3:affectedOrganism
Human Influenza A Virus
n3:casRegistryNumber
13392-28-4
n3:containedIn
n13:271B5A79-363D-11E5-9242-09173F13E4C5 n13:271B5A7A-363D-11E5-9242-09173F13E4C5 n13:271B5A77-363D-11E5-9242-09173F13E4C5 n13:271B5A78-363D-11E5-9242-09173F13E4C5 n13:271B5A75-363D-11E5-9242-09173F13E4C5 n13:271B5A76-363D-11E5-9242-09173F13E4C5 n13:271B5A73-363D-11E5-9242-09173F13E4C5 n13:271B5A74-363D-11E5-9242-09173F13E4C5 n13:271B5A71-363D-11E5-9242-09173F13E4C5 n13:271B5A72-363D-11E5-9242-09173F13E4C5 n13:271B5A70-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5A92-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5A94-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5A95-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5A97-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5A91-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5A90-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5A93-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5A82-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5A8F-363D-11E5-9242-09173F13E4C5